Amgen's Obesity Drug Achieves 20% Weight Loss, Yet Shares Fall
TL;DR Summary
Early data from clinical trials indicate that the new obesity drug MariTide can help patients lose up to 20% of their body weight, offering a promising new treatment option for weight management.
- New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows The New York Times
- Amgen stock slips as obesity drug study disappoints Wall Street Yahoo Finance
- Amgen's obesity drug cuts weight by up to 20%, trial data drags down shares Reuters
- Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound Investor's Business Daily
- Amgen says obesity drug caused up to 20% weight loss after a year, but shares drop 10% CNBC
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
-10%
29 → 32 words
Want the full story? Read the original article
Read on The New York Times